PARP1 and ovarian cancer: It has been recognized that PARP inhibition for the management of breast or ovarian cancers with BRAC1/2 mutations (deficiencies in the HR) is now a well-established approach, in fact over the past decade, four PARPi have been FDA-approved for clinical use as single agents.